4.3 Coagulation Testing and Anticoagulants

Laboratory Coagulation Testing and Anticoagulants

The coagulation laboratory relies on precise functional assays to assess the integrity of the hemostatic system, identify factor deficiencies, and monitor anticoagulant therapies. The cornerstone screening tests include the Prothrombin Time (PT), the Activated Partial Thromboplastin Time (aPTT), and specific assays for fibrin formation and degradation such as Fibrinogen and D-Dimer. Additionally, mixing studies are critical for distinguishing between simple factor deficiencies and the presence of circulating inhibitors.

Prothrombin Time (PT) and the INR

The Prothrombin Time (PT) evaluates the integrity of the extrinsic and common pathways of coagulation (Factors VII, X, V, II, and I). In this assay, citrated patient plasma is incubated at 37°C, and a reagent containing Tissue Factor (thromboplastin) and calcium is added. The time taken for a fibrin clot to form is measured.

The PT is highly sensitive to deficiencies in Factor VII. Because Factor VII has the shortest half-life of all coagulation factors, the PT is the first test to prolong in conditions affecting factor synthesis, such as liver disease or vitamin K deficiency.

Monitoring Warfarin Therapy

The PT is the primary test used to monitor oral anticoagulant therapy with warfarin (Coumadin). Warfarin acts as a Vitamin K antagonist, inhibiting the gamma-carboxylation of the Vitamin K-dependent factors (Factors II, VII, IX, and X).

Because different laboratories use different thromboplastin reagents with varying sensitivities, the PT result alone cannot be standardized across institutions. To solve this, the International Normalized Ratio (INR) was developed. The INR mathematically standardizes the PT result using the International Sensitivity Index (ISI) of the specific reagent batch.

A normal INR is approximately 1.0. For most patients on warfarin therapy (e.g., for atrial fibrillation or DVT), the target therapeutic INR range is 2.0 to 3.0.

Activated Partial Thromboplastin Time (aPTT)

The Activated Partial Thromboplastin Time (aPTT) assesses the integrity of the intrinsic and common pathways (Factors XII, XI, IX, VIII, X, V, II, and I). In this test, the patient's plasma is incubated with a contact activator (such as silica, celite, or kaolin) and partial thromboplastin (a phospholipid substitute lacking tissue factor). Calcium is then added, and the clotting time is recorded.

The aPTT is prolonged in Hemophilia A and B, contact factor deficiencies, and severe common pathway defects.

Monitoring Heparin Therapy

The aPTT is the standard assay for monitoring Unfractionated Heparin (UFH) therapy. Heparin exerts its anticoagulant effect by binding to and significantly accelerating the activity of Antithrombin, a natural inhibitor that predominantly neutralizes Thrombin (IIa) and Factor Xa. A typical therapeutic target for unfractionated heparin is an aPTT of 1.5 to 2.5 times the normal baseline. (Note: Low Molecular Weight Heparins, like enoxaparin, have less effect on the aPTT and are typically monitored using an anti-Xa assay).

Mixing Studies: Deficiencies vs. Inhibitors

When a screening test (like the aPTT) is abnormally prolonged, the laboratory must determine whether the prolongation is due to a factor deficiency or the presence of a circulating inhibitor (such as a specific factor antibody or a Lupus Anticoagulant). This is achieved through a mixing study.

In a 1:1 mixing study, the patient's plasma is mixed with an equal volume of pooled normal plasma (PNP), and the aPTT (or PT) is repeated.

• Correction: If the clotting time corrects to within the normal reference range immediately upon mixing, it indicates a Factor Deficiency. The PNP supplies at least 50% of normal factor levels, which is more than enough to achieve a normal clotting time.
• Failure to Correct: If the clotting time remains prolonged after mixing, it indicates the presence of a Circulating Inhibitor. The antibody or inhibitor in the patient's plasma rapidly neutralizes the factors present in the normal pooled plasma, preventing correction.

Lupus Anticoagulants (LA) are a type of antiphospholipid antibody that bind to the phospholipid surfaces used in the aPTT reagent, interfering with the assembly of coagulation complexes in vitro and causing a prolonged aPTT. Paradoxically, in vivo, patients with LA are at an increased risk for thrombosis, not bleeding.

Fibrinogen and D-Dimer

Fibrinogen (Factor I) is a vital acute-phase reactant and the ultimate substrate of the coagulation cascade. Quantitative fibrinogen assays measure the time it takes for a high concentration of thrombin to convert the fibrinogen in diluted plasma to a clot. Fibrinogen levels are characteristically depleted in consumptive coagulopathies like Disseminated Intravascular Coagulation (DIC).

D-Dimer is a specific marker of fibrinolysis. When plasmin degrades a fully formed, Factor XIII-cross-linked fibrin clot, it releases specific degradation products, the smallest of which is the D-Dimer (two covalently bonded D domains). Because D-Dimer is only generated from the breakdown of cross-linked fibrin (not free fibrinogen), an elevated D-Dimer level proves that both widespread coagulation (thrombin generation) and subsequent fibrinolysis (plasmin generation) have occurred.

The D-Dimer assay is highly sensitive but poorly specific. Therefore, a negative D-Dimer result has a high negative predictive value (NPV), making it exceptionally useful for ruling out deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with low to moderate clinical probability. Markedly elevated D-Dimer levels are a hallmark diagnostic finding in Disseminated Intravascular Coagulation (DIC), accompanied by prolonged PT/aPTT, decreased fibrinogen, and thrombocytopenia.

Fibrin Degradation Products (FDP) and Fibrin Split Products (FSP)

FDP/FSP assays detect fragments generated when plasmin degrades fibrin or fibrinogen. Older serum-based FDP assays are less specific than modern D-dimer methods.

• D-dimer specifically detects cross-linked fibrin degradation products (contains the D-D domain joined by factor XIIIa cross-links). Elevated D-dimer indicates fibrin formation and fibrinolysis (DIC, VTE, trauma, pregnancy, inflammation).
• FDP/FSP may be elevated when either fibrinogen or fibrin is lysed; therefore FDP can rise in primary fibrinogenolysis as well as secondary fibrinolysis.
• Exam distinction: a markedly elevated FDP with a normal or near-normal D-dimer pattern suggests fibrinogenolysis rather than cross-linked fibrin breakdown; in DIC, both FDP and D-dimer are typically elevated, fibrinogen falls, PT/aPTT prolong, and platelets drop.

Always interpret fibrin-split testing with the PT, aPTT, fibrinogen, platelet count, and clinical picture.